Marketing laronidase (Aldurazyme)

Marketing laronidase (Aldurazyme), an enzyme replacement therapy for mucopolysaccharidosis type I (MPS I), requires tailored strategies to address its niche therapeutic area, high costs, and complex patient needs. Here are some effective strategies:

1. Patient-Centric Marketing

  • Focus on Education and Awareness:
    • Since MPS I is a rare condition, raising awareness among patients, caregivers, and advocacy groups is critical.
    • Collaborate with organizations like the Canadian Organization for Rare Disorders (CORD) to educate families about MPS I and treatment options.
  • Support Programs:
    • Provide comprehensive patient support programs, including financial assistance, treatment adherence tools, and access to genetic counseling.

2. Specialist Engagement

  • HCP Education:
    • Offer continuing medical education (CME) courses for pediatricians, geneticists, and metabolic specialists to improve diagnosis and referral rates.
    • Emphasize case studies showcasing the impact of early laronidase intervention on quality of life and disease progression.
  • Peer Networks:
    • Foster collaboration among specialists through conferences and seminars focused on lysosomal storage disorders.
    • Highlight real-world evidence and clinical trial data to reinforce the efficacy of laronidase.

3. Advocacy and Policy Influence

  • Partnerships with Advocacy Groups:
    • Collaborate with rare disease organizations to influence policy decisions and ensure provincial and federal healthcare systems provide adequate coverage for laronidase.
  • Awareness Campaigns:
    • Leverage advocacy days like Rare Disease Day to spotlight the challenges faced by MPS I patients and the benefits of enzyme replacement therapies.

4. Access and Affordability

  • Reimbursement Navigation:
    • Provide resources to help patients and providers navigate Canada’s reimbursement system, ensuring access to therapy through public and private insurance.
    • Engage with provincial formularies to secure listing and coverage under special access programs.
  • Tiered Pricing Models:
    • Consider flexible pricing strategies to address affordability while maintaining the product’s sustainability in the market.

5. Leveraging Data and Outcomes

  • Real-World Evidence:
    • Share long-term patient outcome data to demonstrate sustained benefits, including improved mobility, organ function, and reduced complications.
  • Health Economics Research:
    • Highlight cost-benefit analyses showing how early treatment with laronidase reduces long-term healthcare expenses, including hospitalizations and surgeries.

6. Digital Engagement

  • Patient and HCP Portals:
    • Develop dedicated online platforms to provide resources for both patients and healthcare providers, including treatment guidelines and patient success stories.
  • Social Media:
    • Use social platforms to create communities for patients and caregivers, fostering connection and trust in the therapy.

Would you like help crafting specific educational materials or a detailed breakdown of advocacy group partnerships?

To craft educational materials and establish partnerships for promoting laronidase, here’s a structured plan along with examples of potential partnerships and material ideas:

1. Educational Materials for Patients and Families

Objective: Simplify complex medical information about MPS I and the role of laronidase in treatment.

Examples:

  • Informational Brochures:
    • Key topics: Early symptoms of MPS I, genetic causes, benefits of early treatment, and the therapy process.
    • Include visual aids like symptom timelines or patient stories to make the content relatable.
  • Videos and Animations:
    • Create a short animated explainer on how laronidase works, focusing on enzyme replacement and its impact on reducing glycosaminoglycan (GAG) buildup.
  • Treatment Guidebooks:
    • Comprehensive booklets covering diagnosis, treatment schedules, side effects, and caregiver tips.

Case Study:

Genzyme, the original developer of Aldurazyme, created a patient-friendly guide for enzyme replacement therapies that simplified the complex science for families. Replicating such a guide tailored to Canada’s healthcare system would resonate with local audiences.

2. HCP-Focused Educational Materials

Objective: Empower healthcare professionals (HCPs) with diagnostic tools and treatment updates.

Examples:

  • Clinical Pocket Guides:
    • Concise resources for pediatricians and metabolic specialists on diagnosing MPS I and starting laronidase therapy.
  • Diagnostic Algorithms:
    • Flowcharts to identify MPS I based on symptoms and lab tests, improving early diagnosis.
  • Webinars and CMEs:
    • Offer sessions on the latest advancements in MPS I treatment, including laronidase’s role and emerging therapies.

Case Study:

Shire (now Takeda) successfully engaged geneticists and pediatricians through tailored CME sessions for rare genetic diseases, focusing on improved diagnosis and access.

3. Partnerships with Advocacy Groups

Objective: Collaborate with organizations to expand awareness and policy influence.

Key Organizations:

  1. Canadian Organization for Rare Disorders (CORD):
    • Partner for Rare Disease Day campaigns, emphasizing MPS I and laronidase’s transformative impact.
    • Jointly create patient success stories or video campaigns.
  2. MPS Society Canada:
    • Work with this group to host support webinars, Q&A sessions, and in-person meetups for MPS I patients and families.
  3. Global Genes or Rare Diseases International:
    • Collaborate for international awareness initiatives, focusing on improving access to enzyme replacement therapies globally.

Case Study:

Sanofi Genzyme partnered with advocacy organizations globally to support campaigns like “World Rare Disease Day,” creating impactful awareness videos and community events.

4. Online Resources

Objective: Make resources accessible to patients and HCPs.

Examples:

  • Dedicated Website or Portal:
    • A Canadian-specific resource hub for laronidase, with sections for patients, caregivers, and HCPs. Include:
      • Symptom checkers.
      • A reimbursement guide for Canadian healthcare coverage.
  • Mobile App:
    • Track infusion schedules, manage side effects, and offer direct access to a support hotline.

5. Advocacy Campaigns

Objective: Influence healthcare policies to support affordable access.

Strategies:

  • Develop whitepapers on the long-term cost-effectiveness of early laronidase treatment.
  • Lobby for provincial coverage under Canada’s health system, emphasizing improved quality of life and reduced healthcare costs.

Example Partnership:

Collaborate with CORD to co-sponsor research on healthcare costs avoided by enzyme replacement therapy.

Would you like assistance drafting specific brochures, presentation outlines for HCPs, or campaign scripts?

Here’s a breakdown of tailored materials and campaigns for promoting laronidase (Aldurazyme) in Canada, focusing on both patient and HCP education. These examples include sample outlines and scripts.

1. Patient-Focused Brochure

Title: Living with MPS I: Understanding Treatment Options

Outline:

  • Cover Page:
    • Eye-catching image of a diverse family with a tagline: “Hope through Treatment: Transforming Lives with Laronidase.”
  • Inside Pages:
    • What is MPS I?:
      • Simplified explanation of the disease with infographics showing the role of GAG accumulation.
    • How Laronidase Works:
      • Visual showing enzyme replacement therapy in action, reducing GAG buildup.
    • What to Expect:
      • Outline of infusion process, potential side effects, and frequency of treatment.
    • Support Resources:
      • Include contact details for advocacy groups like the Canadian MPS Society and financial aid programs.
    • Patient Story:
      • Short testimonial from a Canadian patient or caregiver describing their experience with treatment.

2. HCP-Focused Presentation

Title: Advancing Treatment for MPS I: The Role of Enzyme Replacement Therapy

Slide Outline:

  1. Introduction to MPS I:
    • Epidemiology, diagnosis challenges, and progression of untreated disease.
  2. Mechanism of Action:
    • Scientific animation explaining laronidase at the cellular level.
  3. Clinical Outcomes:
    • Data from pivotal trials and long-term studies showing efficacy in improving mobility and reducing complications.
  4. Patient Identification:
    • Highlight early diagnostic tools, such as genetic testing or urine GAG tests.
  5. Support Programs:
    • Outline tools provided by manufacturers for patient and provider support, including adherence tools and reimbursement navigation.
  6. Case Study:
    • Success story of a pediatric patient in Canada achieving significant improvement after treatment initiation.

3. Advocacy Campaign Script

Campaign: Rare, Not Invisible: MPS Awareness

Script Example:

  1. Opening Visuals:
    • Images of children and adults with MPS I engaging in everyday activities.
    • Voiceover: “For the 1 in 100,000 Canadians living with MPS I, every day brings challenges—but also hope.”
  2. Middle Segment:
    • Transition to a visual explanation of laronidase.
    • Voiceover: “Laronidase replaces the missing enzyme, offering a lifeline for those with MPS I.”
    • Include short patient interviews: “Before treatment, I couldn’t walk to the park with my son. Now, it’s our daily routine.”
  3. Closing Call to Action:
    • Text overlay: “Learn more at [dedicated website] or contact the Canadian MPS Society.”

4. Digital Campaign Elements

  • Infographic for Social Media:
    • Title: “Breaking Down Barriers for MPS I Patients in Canada”
    • Key stats: Prevalence, time to diagnosis, and benefits of early treatment.
    • Call to action: Link to patient support resources.
  • Video Ad:
    • Combine the advocacy script with real-world footage of patients receiving treatment in Canadian facilities.

Would you like me to draft one of these elements more thoroughly, such as a specific brochure page or PowerPoint slide?

Let’s start with a patient-focused brochure page that can serve as an engaging, informative resource for laronidase and MPS I. Below is a detailed draft for one of the pages:

Brochure Page: How Laronidase Brings Hope to MPS I Patients

Title Section:

“Empowering Lives Through Treatment”
A closer look at enzyme replacement therapy for MPS I.

What is MPS I?

Mucopolysaccharidosis Type I (MPS I) is a rare genetic condition caused by the body’s inability to produce enough of the enzyme α-L-iduronidase. This leads to the accumulation of glycosaminoglycans (GAGs), which can harm tissues and organs over time.

  • Symptoms:
    • Skeletal abnormalities
    • Respiratory issues
    • Organ enlargement
    • Developmental delays

Without treatment, these symptoms can progress, affecting mobility, quality of life, and lifespan.

How Laronidase (Aldurazyme) Works

Laronidase is a recombinant form of α-L-iduronidase. This enzyme replacement therapy helps:

  • Break down GAGs, reducing buildup in tissues.
  • Improve respiratory function, mobility, and endurance.
  • Slow or prevent the progression of complications.

![Illustration: Diagram of enzyme replacement targeting GAG buildup]

What to Expect from Treatment

  • Administration:
    Laronidase is given as a weekly intravenous (IV) infusion in a clinical setting. Sessions last approximately 3-4 hours.
  • Common Side Effects:
    Some patients may experience mild infusion reactions such as rash, fever, or headache. Your care team will monitor for these and help manage them.

Patient Story

“Before starting laronidase, we struggled with daily tasks. Now, my child is more active, happier, and hopeful about the future.”
— Parent of an MPS I patient, Ontario

Support is Here for You

  • Canadian MPS Society: Assistance and advocacy for families living with MPS I.
  • Financial Aid Programs: Help with insurance coverage or navigating reimbursement policies.
  • Caregiver Tips: Join our webinars for strategies to support loved ones through their journey.

Contact Us Today:
To learn more about MPS I and how laronidase can help, visit [your website URL] or call our support team at 1-800-XXX-XXXX.

Services

Arcus offers clients a unique combination of fact-based industry knowledge and superior functional expertise. Our consultants have an average of over 22 years experience, twice the industry average. Find out more about our growth, change management and  operations services.

At Arcus we believe that a strategy is only as good as the results it delivers. Strategic outcomes are most predictable and effective when companies develop a portfolio of initiatives that are aligned with core competencies and aligned activities enable the company to offer a superior value proposition.

Please contact Arcus for case studies and to discuss how we can help you.

Service coverage

The variety, breadth, and depth of the projects where Arcus can be a resource are made unique by each client’s specific needs. By providing a very small sample of projects we’ve completed, we can help you understand how and when to use our services. Visit the links below to find out more about a specific problem or opportunity you would like to address.

Below is a sample of the range of services that Arcus has provided to clients.

  • A survey of 2,350 consumers and 1,320 business leaders for feedback on sustainability trends
  • Architecting a multi-year change strategy for a Fortune 500 company
  • Mentoring a CEO on organizational change
  • Excellence transformation of a leading B2B services company
  • Creating a new sales deployment model for a healthcare company
  • Developing a position evaluation and compensation model for a professional medical association   
  • Improving services to customer segments by deepening their understanding of customer attitudes

“Arcus manages to consistently deliver tangible results on market research and strategy projects. They combine deep business expertise, powerful research capabilities, and innovative thinking to deliver substantial value.”

– Vice President, Nikon

Data Dashboards
  • Empower your decision-making with comprehensive, trusted data.
  • Gain actionable insights with access to real-time Canadian consumer, business and sector spending and location data.
  • Inform economic policy, investments, sales deployment and strategic plans by looking at trends across different industries and regions in Canada.
  • Influence your businesses’ future growth plans by understanding consumer behaviour

Learn more.

Media Coverage

Arcus has been quoted extensively in media on a range of topics and can offer research studies, insights and ideas. Here are some examples from the Globe and Mail, CTV, Global TV and others.

Off-the-shelf technology or a custom design?  – Globe and Mail

Nordstrom countdown to opening begins – Toronto Star

No lineups outside stores in five years – BNN

Black Friday retail, marketing, and cross-border shopping trends  – BNN

Does global expansion need a local flavour? – Globe and Mail

Art of the Pitch – Protect company’s interests when approaching giants – Globe and Mail